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Abstract
Fenretinide, a synthetic retinoid, induces apoptotic cell death in B-cell non-Hodgkin lymphoma 
(B-NHL) and acts synergistically with rituximab in preclinical models. We report results from a 
phase I–II study of fenretinide with rituximab for B-NHLs.
Eligible diagnoses included indolent B-NHL or mantle cell lymphoma. The phase I design de-
escalated from fenretinide at 900 mg/m2 PO BID for days 1–5 of a 7-day cycle. The phase II 
portion added 375 mg/m2 IV rituximab weekly on weeks 5–9 then every 3 months. Fenretinide 
was continued until progression or intolerance.
Thirty-two patients were treated: 7 in phase I, and 25 in phase II of the trial. No dose-limiting 
toxicities were observed. The phase II component utilized fenretinide 900 mg/m2 twice daily with 
rituximab. The most common treatment-related adverse events of grade 3 or higher were rash (n = 
3) and neutropenia (n = 3). Responses were seen in 6 (24%) patients on the phase II study, with a 
median duration of response of 47 months (95% confidence interval, 2 – 56).
The combination of fenretinide and rituximab was well tolerated, yielded a modest overall 
response rate, but with prolonged remission durations. Further study should focus on identifying 
the responsive subset of B-NHL.
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Background
Indolent B-cell non-Hodgkin lymphoma (B-NHL), chronic lymphocytic leukaemia (CLL) 
and mantle cell lymphoma (MCL) are together among the most common types of incurable 
B-cell malignancies. Rituximab, a chimeric mouse anti-human CD20 monoclonal antibody, 
is an essential component of treatment for CD20-expressing B-NHLs, and has a diverse 
repertoire of actions, including induction of apoptosis, activation of antibody-dependent 
cellular cytotoxicity, and complement-dependent cytotoxicity (Keating, 2010). Retinoids are 
a class of compounds both synthetic and natural which are analogues of Vitamin A. The 
retinoid acid and retinoid X receptors are two classes of receptors that these compounds act 
through (Barna et al., 2005). N-(4-hydroxyphenyl) retinamide (4-HPR), also known as 
fenretinide, is a retinoid that has shown both anti-proliferative and pro-apoptotic in pre-
clinical studies (Faderl et al., 2003, Lovat et al., 2000, Pergolizzi et al., 1999, Shan et al., 
2001).
Our group has demonstrated that fenretinide alone, at concentrations as low as 2µM, could 
induce apoptosis in B-NHL cell lines and generate synergistic killing of malignant B-cells in 
combination with rituximab (Shan et al., 2001). These data were corroborated by human 
xenograft models demonstrating supra-additive tumour control and improved survival with 
concurrent rituximab and fenretinide over the individual single agents and that this effect 
was mediated by caspase induction and apoptosis (Gopal et al., 2004). Prior studies have 
used a dose of 900 mg/m2 twice daily in oral formulation, which has proven to be tolerable 
and results in potentially efficacious peak serum levels (Cheung et al., 2009, William et al., 
2009). In this translational study, we dosed fenretinide at 900 mg/m2 twice daily for 5 days 
per week, with a 2-day drug holiday, for 4 weeks mirroring the regimen used in the in-vivo 
preclinical studies. We also hypothesized that the 2-day drug holiday would allow 
endogenous retinol levels to partially recover, potentially reducing nyctalopia. We then 
combined this regimen with rituximab to evaluate its safety and potential efficacy for 




Inclusion criteria for this study were a diagnosis of a CD20+ B-NHL, either newly 
diagnosed, or previously treated. Other eligibility criteria were age ≥ 18 years, Eastern 
Cooperative Oncology Group (ECOG) performance status ≤ 2, and a pre-treatment serum 
bilirubin and creatinine < 2 times the upper limit of normal. Measureable disease was 
required, defined as lesions that can be measured in two dimensions by conventional 
imaging and a greatest transverse diameter of ≥ 1 cm.
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Study Design and Treatment
This open-label, phase I/II study was conducted at the Fred Hutchinson Cancer Research 
Center, the University of Washington, and Seattle Cancer Care Alliance, Seattle, WA 
(ClinicalTrials.gov identifier: NCT00288067). Patients were recruited from October 2005 
until October 2009. Primary data analysis was performed in June 2015. The study was 
approved by the institutional review board at Fred Hutchinson Cancer Research Center. 
Written informed consent was obtained in accordance with the Declaration of Helsinki.
The phase I component utilized a dose de-escalation design in cohorts of 6 patients starting 
at the maximal dose of 900 mg/m2 by mouth twice daily, on days 1 to 5 followed by a 2-day 
drug holiday (Figure 1a). Reduction in the dose level to 700 mg/m2 was required in the next 
cohort if 2 or more of the 6 patients experienced a dose limiting toxicity (DLT) within the 
first 4 weeks of therapy. A DLT was defined as any related toxicity of grade 4 or 5 on or 
before the completion of 4 weeks of therapy. Patients without DLTs or disease progression 
were allowed to continue beyond 4 weeks until disease progression, toxicity or voluntary 
withdrawal.
Patients in the phase II cohort expansion portion were treated at the dose level derived from 
phase I with the identical 5 of 7-day schedule. In addition, rituximab was administered at a 
dose of 375 mg/m2 intravenously, weekly for 4 weeks, starting at week 5 followed by a 
single maintenance infusion of 375 mg/m2 rituximab every 3 months (Figure 1b). Treatment 
was continued until unacceptable toxicity, disease progression, voluntary withdrawal or 
cessation of drug supply.
Study Assessments
Baseline evaluations included history and physical examination, complete blood count with 
differential, comprehensive metabolic panel, peripheral blood flow cytometry, molecular 
studies for immunoglobulin heavy chain clonality, and bone marrow aspirate and biopsy. 
Positron emission tomography-computed tomography (PET-CT) and contrast-enhanced CT 
were obtained, followed by PET-CT and contrast-enhanced CT scans at week 5, month 3, 
and every 6 months thereafter. Clinical response was determined by the principal 
investigators of the study per the International Response Criteria for Non-Hodgkin 
Lymphomas and the National Cancer Institute-Sponsored Working Group Guidelines for 
CLL (Cheson et al., 1996, Cheson et al., 1999). Correlative studies included apoptosis 
markers from blood and bone marrow.
Assessments of apoptosis markers were obtained at weeks 1, 2, 3, 4/5, and months 2 and 3, 
and then every 3 months thereafter. Samples were screened for residual disease using a 
routine clinical flow cytometric assay; this allowed identification of informative reagents for 
gating of the neoplastic population, typically CD19, CD20, CD5 and/or CD10. These gating 
reagents were combined with Annexin V and Caspase 3 to assess early and late apoptosis of 
the neoplastic cells using standard flow cytometric methods. In addition, the ratio of the pro-
apoptotic and anti-apoptotic molecules BAX and BCL2 were assessed on the neoplastic cells 
using a standard fixation and permeabilization procedure (Fix & Perm; Invitrogen, Carlsbad, 
CA, USA).
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High performance liquid chromatography measurements of plasma retinol and fenretinide 
were obtained at baseline and before and after the 2-day weekly drug holiday to reflect peak 
and trough levels. Long-term pharmacokinetic data, collected at 3-month intervals post-
month 3, were also obtained.
Statistical Analysis
The primary endpoint of the phase I study was to evaluate the safety of fenretinide delivered 
in a 5 of 7-day regimen. Secondary endpoints included pharmacokinetic studies, 
determination of the intratumoural concentrations of fenretinide, evaluation of the in vivo 
mechanism of action of fenretinide, identification of predictors of response to fenretinide 
and estimation of response rates.
The primary endpoint of the phase II study was to estimate the overall response rate (ORR) 
of fenretinide and rituximab in patients with B-NHL. Secondary endpoints included overall 
survival (OS), progression-free survival (PFS), duration of response, pharmacokinetic 
studies, intratumoural concentrations of fenretinide, identification of predictors of response 
and evaluation of the in vivo mechanism of action of fenretinide. PFS was defined as the 
time from the start of study treatment to progression, or to death as a result of any cause. OS 
was defined as the time from start of study treatment until date of death from any cause. 
Duration of response was defined as the time from the first documented objective response 
until progression or death.
The ORR per the independent review was calculated. Response-evaluable patients must have 
received at least 4 weeks of fenretinide for the phase I study, and 8 weeks for the phase II 
study, unless discontinuation was due to progressive disease. Median and two-sided 95% 
confidence intervals (CIs) were estimated for OS, PFS and duration of response. Kaplan-
Meier curves were created for OS and PFS.
Results
Patients
Patient characteristics are summarized in Table 1. Thirty-two patients enrolled in the study; 
7 patients enrolled in the phase I, and 25 patients enrolled in the phase II study. The median 
age of patients was 64 years (range, 40 to 78 years). The majority of the patients were men, 
26 patients (81%), with 6 women (19%). Patients had received a median of 1 prior regimen 
and 69% had received prior rituximab with 8 suffering rituximab-refractory disease. The 
most common histology present was CLL/small lymphocytic lymphoma (SLL) in 13 
patients (41%). Other histologies were follicular lymphoma (FL) in 10 patients (31%), MCL 
in 7 patients (22%), lymphoplasmacytic lymphoma in 1 patient (3%), and mantle zone 
lymphoma (MZL) in 1 patient (3%).
In the phase I study, the dose chosen was 900 mg/m2 twice daily; this dose was moved 
forward to the phase II study.
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For the phase I component, patients were treated for a median of 0.9 months (range, 0.3 – 
9.4 months). The median number of cycles administered was 1 (range, 1 – 4); 1 patient 
discontinued due to a drug eruption after 1 cycle of treatment. In the phase II study, patients 
were treated for a median of 6.8 months (range, 0.2 – 54.3 months) and received a median 3 
cycles of treatment (range, 1 – 18). A total of 3 patients discontinued drug on the phase II 
study, due to photosensitivity in 1, drug rash in 1, and gastrointestinal distress in the final 
patient. Following completion of the study, 5 patients (16%) remained on rituximab on a 
maintenance schedule.
Safety Profile
The most common treatment-related adverse events of any grade were reversible nyctalopia 
(56%), other eye disorders (53%), rash (38%), decreased lymphocyte count (25%), 
photosensitivity (25%), diarrhoea (22%), decreased platelet count (22%) and decreased 
neutrophil count (19%) (Table II). A total of 3 patients (9%) on study discontinued treatment 
early due to toxicity from therapy. In 2 of these patients, discontinuation occurred during the 
first week of therapy due to development of a diffuse maculo-papular eruption; in both 
patients, the rash abated following cessation of therapy. One patient discontinued treatment 
on day 140 due to gastrointestinal symptoms, weakness and fatigue.
Twenty-two patients (69%) experienced eye disorders of any grade. Of these patients, 18 
experienced nyctalopia (56%). Of these 18 patients, 3 had severe enough night vision 
impairment to impact their activities of daily living and 7 required either dose reduction or 
brief discontinuation of treatment due to nyctalopia. All patients who required either dose 
reduction or brief treatment holidays had improvement in nyctalopia. Descriptions of night 
vision impairment ranged from mild changes, to more moderate difficulty with navigation at 
night.
Three patients (9%) on this study had Grade 3 related dermatological eruptions while on 
treatment. In all three patients, this was described as a morbilliform drug eruption. In 2 
patients, the eruption appeared within 2 weeks of commencing treatment with fenretinide. In 
1 patient, the reaction was severe enough to require systemic steroids and hospital 
admission.
Efficacy
The overall disease control rate (complete response + partial response + stable disease for ≥ 
6 months) for all patients on study was 56%, with a median duration of disease control of 15 
months (range, 6– 58 months). Documented tumour reductions occurred in 91.7% of 
patients on the phase II study (Figure 2c).
No patient had a response in the phase I study, with a median PFS of 4 months (95% CI, 0 to 
not reached), and a median OS was 108 months (95% CI, 65 to not reached) (Figure 2a). 
Two patients in the phase I portion had MCL; one patient experienced stable disease (SD) 
lasting 35 months (having had a 6-month prior remission to rituximab monotherapy), and the 
other had SD lasting 25 months, with a 37.3% tumour reduction, the most marked reduction 
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of the group (prior receipt of 4 lines of therapy; most recent being bortezomib, with a 5-
month response duration). Of the 3 patients with CLL/SLL, 1 had SD lasting 12 months, and 
2 either did not respond or had SD lasting less than 1 month. Two patients had FL; 1 
discontinued drug early due to toxicity, and the other had early progression after less than 1 
month of treatment.
In the phase II component, 6 (24%) patient’s disease responded (Figure 2b), with 2 (8%) 
achieving complete response (CR) (1 FL, 1 MCL) and 4 (16%) achieving partial response 
(PR) (2 CLL/SLL, 1 FL, 1 MCL). In addition, 16 (64%) patients had SD. The median PFS 
was 8 months (95% CI, 4 – 31 months), and the median OS was not reached (95% CI, 33 
months to not reached) (Figure 2b). Median duration of response was 47 months (95% CI, 2 
– 56). The median PFS for MCL (n = 5) was 8 months, for FL (n = 8) was 17 months, for 
MZL (n = 1) was 7 months, and for CLL/SLL (n = 10) was 4 months. The median PFS for 
the 2 patients who achieved a CR was 59.5 months.
This study closed at the end of 2012 when the National Cancer Institute ended provision of 
fenretinide. At that time, 4 patients, all of whom had an objective response, were on 
continuous fenretinide and rituximab without disease progression, and had to stop therapy 
on study. Of these patients, one had MCL, with a 56-month duration of response after a CR, 
who continued on maintenance rituximab alone with no disease progression to date. Another 
patient with FL, who also had a CR, had a 50-month duration of response, continued on 
rituximab maintenance after discontinuation of fenretinide, but experienced disease 
progression 12 months later and started chlorambucil and rituximab. After a 58-month 
duration of response, a patient with FL who had a PR completed 3 additional cycles of 
maintenance rituximab and remains progression-free to date. A final patient with MCL with 
a PR, had a 44-month duration of response and continued on maintenance rituximab after 
discontinuation of fenretinide. He progressed 2 years later and has started ibrutinib.
Two other patients had an objective response. One patient with CLL/SLL who had a PR, 
sustained their response for 38 months before developing progressive disease and receiving 
subsequent therapy. Another patient with CLL/SLL, who had an initial PR to treatment, 
developed progressive disease within 2 months and went on to receive subsequent treatment 
with bendamustine, mitoxantrone and rituximab.
The majority of patients received more than 1 prior line of therapy. Only 1 patient was 
previously treated with rituximab monotherapy. This patient had FL, and had a 3-year 
response to rituximab as a single agent; in contrast, there was only a 12-month duration of 
response with fenretinide and rituximab on study.
Pharmacokinetic Studies
The pharmacokinetic studies are depicted in Table III. The median peak (pre-drug holiday) 
and trough (post-drug holiday) plasma fenretinide values were 12.9 µM (range, 0.7 to 33.5 
µM) and 2.6 µM (range, 0.0 to 6.9 µM), respectively. Unlike other retinoids, there did not 
appear to be induced catabolism of fenretinide as concentrations did not appreciably change 
over time. Fenretinide concentrations within the bone marrow consistently exceeded that of 
the plasma at the same time points. We evaluated plasma retinol levels as a potential 
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pharmacodynamic marker of toxicity. The median baseline plasma retinol was 5.5 µM 
(range, 1.7 – 15.3 µM) and predictably dropped to a median of 0.5 µM (range, 0.0 to 2.3 µM) 
at the first measured pre-drug holiday time point. Plasma retinol levels partially recovered 
following the 2-day drug holiday to a median of 1.3 µM (0.0 – 3.1µM).
Apoptosis studies
In patients who had evidence of circulating tumour cells (n = 13), we assessed the impact of 
fenretinide and rituximab on flow cytometrically quantified BCL2 and BAX expression, as 
well as annexin V as a measure of apoptosis. There was no correlation between BCL2 
expression, BAX expression, BAX to BCL2 ratios or annexin V expression and clinical 
response or toxicity.
Discussion
This phase I/II study was the first to evaluate the combination of fenretinide and rituximab 
and demonstrated low response rates in B-NHLs; it was well tolerated with predictable, 
reversible toxicities with up to 4.5 years of continuous therapy. In contrast to the most 
widely used therapeutic retinoid in oncology, all-trans retinoic acid (ATRA), we have shown 
that fenretinide in an oral formulation has a stable pharmacokinetic profile. Early studies of 
ATRA in patients with acute promyelocytic leukaemia demonstrated diminishing plasma 
concentrations of drug within 1–2 weeks of commencing continuous oral therapy (Adamson, 
1994, Adamson et al., 1995, Muindi et al., 1992). In our study, the results of 
pharmacokinetic studies for up to 12 months post-initiation of treatment document 
consistent plasma concentrations of fenretinide with oral dosing. We were also able to show 
higher concentrations of fenretinide within bone marrow as compared to the plasma, 
potentially explained by the high-lipid content of the marrow space.
In keeping with prior studies, the toxicity profile of fenretinide was tolerable and reversible. 
The principal toxicity associated with fenretinide, nyctalopia, has been reported in prior 
early-phase studies of fenretinide (Cheung et al., 2009, Maurer et al., 2013, Moore et al., 
2010, Vaishampayan et al., 2005). As with previous observations of nyctalopia from 
fenretinide, all cases in our study were reversible, and none discontinued therapy 
permanently due to night blindness. The nyctalopia which results from fenretinide has been 
hypothesized to be secondary to reduced retinol levels in the blood, which can result in 
decreased visual pigments in the retina which are responsible for night vision (Formelli et 
al., 1989). Our strategy of a drug holiday demonstrated a partial recovery of retinol levels 
without significantly compromising fenretinide concentrations.
Despite promising results in one preventive trial in breast cancer using fenretinide, the 
majority of clinical trials evaluating fenretinide for cancer treatment have not shown a 
significant anti-tumour effect (Cheung et al., 2009, Puduvalli et al., 2004, Schneider et al., 
2009, Vaishampayan et al., 2005). Given the high dose requirements necessary to achieve 
therapeutic levels of fenretinide, and the burden on the patient to take so many pills every 
day, one potential hypothesis for lack of efficacy might be therapeutic drug levels were not 
achieved. However, we performed correlative pharmacokinetic studies demonstrating that 
trough fenretinide levels from bone marrow and plasma that had previously been shown to 
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be efficacious in induction of apoptosis in preclinical studies were present (Gopal et al., 
2004, Shan et al., 2001). Induction of free radicals is another potential mechanism for the 
pro-apoptotic effect of fenretinide; potentially, the limited clinical effect in patients with B-
NHL is the relative hypoxia of lymph nodes (Delia et al., 1997).
In summary, in this phase I/II study of fenretinide and rituximab in patients with B-NHLs, 
we found that this combination was tolerable for long-term use and yielded modest response 
rates. Many patients experienced prolonged disease control comparable to approved agents 
for indolent B-NHL, but the contribution of fenretinide beyond that provided by rituximab 
cannot be ascertained by this study design Future studies with fenretinide in lymphoma may 
require novel formulations, such as nanoparticulate or liposomal drug delivery systems, as 
well as identification of optimal combinations to further augment the proapoptotic effect of 
this agent (Pignatta et al., 2014, Sabnis et al., 2013).
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Fenretinide is an orally bioavailable retinoid compound shown to act synergistically with 
rituximab in translational models. We conducted a phase I/II study of fenretinide and 
rituximab in patients with indolent B-cell non-Hodgkin lymphoma. The combination was 
well tolerated with predictable and reversible toxicities, and modest response rates. 
Further study should focus on identifying optimal drug combinations to augment these 
anti-tumour effects.
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Figure 1. Study schema for phase I portion (1a), and phase II portion (1b)
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Figure 2. Kaplan-Meier plots for PFS and OS for phase I patients (2a) and phase II patients (2b). 
Waterfall plot for phase II patients (2c)
PFS, progression-free survival; OS, overall survival; CLL/SLL, Chronic lymphocytic 
leukaemia/small lymphocytic lymphoma
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Table I
Demographics and patient characteristics
Characteristics Patients,
Male (%) 26 (81)
Median age (range) 64 (40 – 78)
Median number of prior chemotherapy regimens (range) 1 (0 – 1)
CD20 positive (%) 31 (97)
Prior hematopoietic stem cell transplantation (%) 4 (13)
Eastern Cooperative Oncology Group Performance Status (%)
  0 26 (81)
  1 5 (16)
  2 1 (3)
Median number of extranodal sites (range) 1 (1 – 3)
Prior rituximab (%) 22 (69)
Histology (%)
  Chronic lymphocytic leukaemia/small lymphocytic lymphoma 13 (41)
  Follicular lymphoma 10 (31)
  Mantle cell lymphoma 7 (22)
  Lymphoplasmacytic lymphoma 1 (3)
  Marginal zone lymphoma 1 (3)
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